MGuard mesh-covered stent for treatment of ST-segment elevation myocardial infarction with high thrombus burden despite manual aspiration

dc.contributor.authorRomaguera, Rafael
dc.contributor.authorGómez Hospital, Joan Antoni
dc.contributor.authorSánchez Elvira, Guillermo
dc.contributor.authorGómez Lara, Josep
dc.contributor.authorFerreiro, José Luis
dc.contributor.authorRoura i Ferrer, Gerard
dc.contributor.authorGracida Blancas, Montserrat
dc.contributor.authorHoms, Silvia
dc.contributor.authorTeruel, Luís M.
dc.contributor.authorCequier Fillat, Àngel R.
dc.date.accessioned2020-02-25T09:01:28Z
dc.date.available2020-02-25T09:01:28Z
dc.date.issued2013-02-18
dc.date.updated2020-02-25T09:01:28Z
dc.description.abstractObjectives: To assess the usefulness of the MGuard stent in patients with ST‐segment elevation myocardial infarction (STEMI) in whom a high thrombus burden persists after manual aspiration. Background: In some patients with STEMI, a high thrombus burden may persist after manual aspiration. These patients may be at high risk of distal embolization and therefore impaired myocardial reperfusion. The MGuard is a novel mesh‐covered stent designed to minimize thrombus embolization. Methods: Single‐arm, prospective registry of patients with STEMI and high thrombus burden after aggressive thrombus aspiration treated with the MGuard stent. High thrombus burden was defined as thrombus burden grade 4 or 5 according to the TIMI score. Lesions with a side branch ≥2 mm and patients with cardiogenic shock were not included. The study end‐points were proportion of final TIMI 3 flow, normal myocardial blush, and complete ST‐segment resolution. Results: Fifty‐six patients were included. After MGuard stent implantation >85% of cases had thrombus score = 0. Final TIMI 3 flow was achieved in 82% of cases, normal myocardial blush in 55%, and complete ST‐segment resolution in 59%. Occlusion of a side branch (<2 mm) occurred in 2 cases (3.5%), embolization to a distal branch in 5 cases (8.9%), and transient no‐reflow in 4 cases (7.1%). Major adverse cardiac events rate at 9 months was 3.6%, including 1 definite acute stent thrombosis and 1 target‐vessel revascularization. Conclusions: The MGuard stent may be useful to prevent distal embolization in patients with STEMI and high thrombus burden despite mechanical aspiration.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec633061
dc.identifier.issn0896-4327
dc.identifier.urihttps://hdl.handle.net/2445/151121
dc.language.isoeng
dc.publisherWiley Hindawi Publishing
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1111/j.1540-8183.2013.12011.x
dc.relation.ispartofJournal of Interventional Cardiology, 2013, vol. 26, num. 1, p. 1-7
dc.relation.urihttps://doi.org/10.1111/j.1540-8183.2013.12011.x
dc.rightscc-by (c) Romaguera, Rafael et al., 2013
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationInfart de miocardi
dc.subject.classificationPròtesis de Stent
dc.subject.otherMyocardial infarction
dc.subject.otherStents (Surgery)
dc.titleMGuard mesh-covered stent for treatment of ST-segment elevation myocardial infarction with high thrombus burden despite manual aspiration
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
633061.pdf
Mida:
185.54 KB
Format:
Adobe Portable Document Format